Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors
摘要:
A series of novel, selective TNF-alpha converting enzyme inhibitors based on 4-hydroxy and 5-hydroxy pipecolate hydroxamic acid scaffolds is described. The potency and selectivity of TACE inhibition is dramatically influenced by the nature of the sulfonamide group which interacts with the S1' site of the enzyme, Substituted 4-benzyloxybenzenesulfonamides exhibit excellent TACE potency with > 100x selectivity over inhibition of matrix metalloprotease-1 (MMP-1). Alkyl substituents on the ortho position of the benzyl ether moiety give the most potent inhibition of TNF-alpha release in LPS-treated human whole blood. (C) 2002 Elsevier Science Ltd. All rights reserved.
Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors
摘要:
A series of novel, selective TNF-alpha converting enzyme inhibitors based on 4-hydroxy and 5-hydroxy pipecolate hydroxamic acid scaffolds is described. The potency and selectivity of TACE inhibition is dramatically influenced by the nature of the sulfonamide group which interacts with the S1' site of the enzyme, Substituted 4-benzyloxybenzenesulfonamides exhibit excellent TACE potency with > 100x selectivity over inhibition of matrix metalloprotease-1 (MMP-1). Alkyl substituents on the ortho position of the benzyl ether moiety give the most potent inhibition of TNF-alpha release in LPS-treated human whole blood. (C) 2002 Elsevier Science Ltd. All rights reserved.
Asymmetric Synthesis of 4- and 5-Substituted Pipecolic Esters by Ring-Closing Metathesis and Palladium-Catalyzed Formate Reduction
作者:Chong-Si Sun、Yu-Shiang Lin、Duen-Ren Hou
DOI:10.1021/jo8008885
日期:2008.9.1
Asymmetric synthesis of 4- and 5-substituted pipecolic esters was achieved by the sequence of allylation, ring-closing metathesis, and palladium-catalyzed formate reduction.
NEW ANTIBIOTICS TARGETING MYCOBACTERIA
申请人:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
公开号:US20200325139A1
公开(公告)日:2020-10-15
The present invention relates to a compound of the folowing formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a dmg, notably in the treatment of a disease caused by mycobacteria, as well as pharmaceutical compositions containing such a compound and a process to prepare such a compound.
Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors
作者:Michael A. Letavic、Matt Z. Axt、John T. Barberia、Thomas J. Carty、Dennis E. Danley、Kieran F. Geoghegan、Nadia S. Halim、Lise R. Hoth、Ajith V. Kamath、Ellen R. Laird、Lori L. Lopresti-Morrow、Kim F. McClure、Peter G. Mitchell、Vijayalakshmi Natarajan、Mark C. Noe、Jayvardhan Pandit、Lisa Reeves、Gayle K. Schulte、Sheri L. Snow、Francis J. Sweeney、Douglas H. Tan、Chul H. Yu
DOI:10.1016/s0960-894x(02)00183-x
日期:2002.5
A series of novel, selective TNF-alpha converting enzyme inhibitors based on 4-hydroxy and 5-hydroxy pipecolate hydroxamic acid scaffolds is described. The potency and selectivity of TACE inhibition is dramatically influenced by the nature of the sulfonamide group which interacts with the S1' site of the enzyme, Substituted 4-benzyloxybenzenesulfonamides exhibit excellent TACE potency with > 100x selectivity over inhibition of matrix metalloprotease-1 (MMP-1). Alkyl substituents on the ortho position of the benzyl ether moiety give the most potent inhibition of TNF-alpha release in LPS-treated human whole blood. (C) 2002 Elsevier Science Ltd. All rights reserved.